Prospective Case-control Study in Patients With PAA

Sponsor
Rebecka Hultgren (Other)
Overall Status
Recruiting
CT.gov ID
NCT04188808
Collaborator
Karolinska University Hospital (Other), Karolinska Institutet (Other), Stockholm South General Hospital (Other), Sahlgrenska University Hospital, Sweden (Other)
130
2
2
123
65
0.5

Study Details

Study Description

Brief Summary

The overall objective is to highlight different aspects of care in patients with PAA before and after treatment, and identifying factors that influence the outcome of PAA patients.

Condition or Disease Intervention/Treatment Phase
  • Other: Bypass surgery
N/A

Detailed Description

An aneurysm is most commonly defined as a permanent focal dilatation of an artery to 1.5 times its normal diameter. While the abdominal aorta is the most common site of aneurysm formation, the popliteal artery (PA) represents the second most common site of aneurysm formation, accounting for more than 70 percent of all peripheral aneurysms. A popliteal artery aneurysm (PAA) is a focal dilatation of the popliteal artery (red arrow). PAAs are rare in the general population but more commonly found in patient populations with other aneurysms, such as abdominal aortic aneurysm (AAA). Within the general population, PAAs are predominantly found in men and are extremely rare in women. There are few studies on the prevalence of PAAs in healthy individuals, but 14-19% of male and 12% of female AAA patients have PAAs. There is no clear correlation between the diameter of the AAA and the prevalence of PAA. There is furthermore a lack of consensus of the precise arterial diameter that defines a PAA.

It is paramount to identify and treat PAA patients before acute symptoms develop, given the high risk of major complications associated with acute presentation, such as major amputation. Unfortunately, there is a lack of knowledge of the natural history for PAAs, which is why surgical procedures are recommended mainly based on clinical experience and guidelines developed from insufficient scientific information. The preventive purpose, more specifically to prevent the risk of acute symptom development, should be evaluated against the frequency of complications inflicted by surgical treatment, so called "surgical risk". For this reason, it is important to evaluate the patients' health-related quality of life (HRQoL) before and after treatment in order to determine how the surgical treatment affect patients. In general, the Health-Related Quality of Life (HRQoL) is therefore emerging as an important outcome measure for interventions designed to improve patient's health, well-being, or both. There is very limited prior knowledge of HRQoL outcomes following surgical treatment of PAAs and the PAA patient's HRQoL, and whether-and to what extent- it becomes affected by the surgical treatment, is yet unknown. The surgical treatment in PAA patients and patients with peripheral arterial disease (PAD), are comparable whereas the underlying pathologies are distinct. Thus, peripheral arterial disease patients commonly experience substantial symptom relief following a surgical intervention (i.e. lower limb pain is alleviated, or ischemic wound healing is promoted). By contrast, PAA patients are often asymptomatic prior to surgery. It is therefore conceivable that a surgical intervention in PAA patients translates to a lower HRQoL after surgery than what is observed following bypass surgery for PAD. However, this needs to be further explored and confirmed in prospective studies.

Aim To investigate whether the QoL of PAA patients compared to PAD patients after surgical and potential changes over time.

Hypothesis Compared to PAD patients, femoropopliteal/femorodistal bypass surgery interventions undertaken on PAA patients result in a more pronounced negative HRQoL impact.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
130 participants
Allocation:
Non-Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Health Services Research
Official Title:
A Prospective Case-control Study of the Quality of Life in Patients With Aneurysmatic or Occlusive Disease in the Lower Limb
Actual Study Start Date :
Sep 1, 2018
Anticipated Primary Completion Date :
Jan 1, 2023
Anticipated Study Completion Date :
Dec 1, 2028

Arms and Interventions

Arm Intervention/Treatment
Experimental: Popliteal artery aneurysm

Asymptomatic popliteal artery aneurysm patients will undergo surgery with a femoropopliteal/femorodistal bypass

Other: Bypass surgery
All patients scheduled for elective surgery of PAA and PAD.

Active Comparator: Peripheral artery disease

Patients with peripheral artery disease defined as (ankle - brachial index, ABI <0.5 or typical symptoms); intermittent claudication (IC), or resting pain and/or minor tissue loss. Will undergo surgery with a femoropopliteal/femorodistal bypass

Other: Bypass surgery
All patients scheduled for elective surgery of PAA and PAD.

Outcome Measures

Primary Outcome Measures

  1. SF-36 [Five years]

    A 36-item questionnaire that measures 8 dimensions of physical and mental health. ( 0-100) Positive if high

Secondary Outcome Measures

  1. EQ-5D [Five years]

    EQ-5D is a standardized instrument for measuring generic health status (0-100) 100 best Health and 0 worst helath

Other Outcome Measures

  1. PHQ-9 PHQ-9 [Five years]

    Depressive symptoms were assessed with the validated nine-item. Patient Health Questionnaire. The PHQ provides a dichotomous measure of depressive symptoms ( 0- 30; below 4 = no deression; 10 or above = depression)

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • All patients scheduled for elective surgery of PAA (asymptomatic)

  • All patients scheduled for elective surgery of PAD

  • Elective open surgery

  • Intermittent claudication

  • Resting pain or very limited minor tissue loss

Exclusion Criteria:
  • Cognitive failure

  • Major tissue loss

  • severe pain

  • if one cannot assimilate information in Swedish and understand the questionnaires

Contacts and Locations

Locations

Site City State Country Postal Code
1 Sahlgrenska University Hospital Gothenburg Sweden
2 Karolinska University Hospital Stockholm Sweden

Sponsors and Collaborators

  • Rebecka Hultgren
  • Karolinska University Hospital
  • Karolinska Institutet
  • Stockholm South General Hospital
  • Sahlgrenska University Hospital, Sweden

Investigators

  • Principal Investigator: Rebecka Hultgren, Prof, Karolinska Instutet

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Rebecka Hultgren, Principal Investigator, Karolinska University Hospital
ClinicalTrials.gov Identifier:
NCT04188808
Other Study ID Numbers:
  • NPAA0831365
First Posted:
Dec 6, 2019
Last Update Posted:
Feb 23, 2021
Last Verified:
Feb 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Rebecka Hultgren, Principal Investigator, Karolinska University Hospital
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 23, 2021